Introduction
The majority of human tumors is of epithelial origin, and a frequently used model for studying epithelial carcinogenesis is the initiation-promotion model of tumorigenesis in mouse skin (1, 2) . Epidermal tumors can be produced by a single application of a subthreshold (initiating) dose of a carcinogen *Abbreviations: DFMO, α-difluoromethylornithine; DMBA, 7,12-dimethylbenz [a] anthracene; H&E, hematoxylin and eosin; ODC, ornithine decarboxylase; PCNA, proliferating-cell nuclear antigen; TGF, transforming growth factor; TPA, 12-O-tetradecanoylphorbol-13-acetate; H&E, hematoxylin and eosin; PCNA, proliferating-cell nuclear antigen; TGF, transforming growth factor.
followed by repeated applications of a tumor-promoting agent such as 12-O-tetradecanoylphorbol-13-acetate (TPA*). One of the earliest events following treatment with a tumor promoter is a large, rapid, and transient induction in ornithine decarboxylase (ODC) activity, which is the first and rate-limiting enzyme in polyamine biosynthesis (3) (4) (5) (6) . Elevated ODC activity has long been suspected to play an important role in tumorigenesis, largely because of its early induction by tumor promoters (3) (4) (5) (6) and to studies using inhibitors of ODC (7) (8) (9) (10) . For instance, α-difluoromethylornithine (DFMO), which is a specific and irreversible inhibitor of ODC, inhibits the development of skin tumors in carcinogen-treated mice when it is given during the promotion phase (9, 10) .
Whereas ODC overexpression alone does not transform normal, diploid keratinocytes or fibroblasts (11) , it does directly transform NIH3T3 cells (12, 13) and enhances the tumorigenicity of pre-malignant epidermal cells that are known to possess an activated Ha-ras gene (11) . Furthermore, elevated levels of ODC and polyamines confer an invasive phenotype to premalignant epithelial cells (14) . Recently, transgenic mice in which ODC overexpression is targeted to epidermal keratinocytes have been used in a classical initiation-promotion model of skin carcinogenesis to show that ODC epidermal overexpression is sufficient in itself to 'promote' squamous papilloma formation following a single subthreshold dose of a carcinogen (15) . This is in contrast with the carcinogeninitiated normal littermate mice that do not express the ODC transgene and that do not develop tumors unless treated repeatedly with a chemical tumor promoter such as TPA. Taken together, these studies indicate that increased basal levels of ODC and polyamines play a causal role in the development of tumors by driving the continued proliferation and selective clonal expression of initiated cells in an epithelial tissue.
Chemically-initiated tumors possess multiple genetic lesions since chemical carcinogens target many genes and pathways. The activation of c-Ha-ras is an early genetic change in both the development of human tumors (16) and in mouse skin carcinogenesis that results from an initiating dose of a carcinogen (17) . Studies using several transgenic ras mouse models, including the TG.AC transgenic mouse, have reinforced previous evidence that suggests that a mutated ras can serve as an initiating event in skin carcinogenesis (18) (19) (20) . TG.AC mice carry a v-Ha-ras transgene that has point mutations in codons 12 and 59 and is fused to the promoter of the mouse embryonic ζ-globin gene (18) . Unlike other ras transgenic mice (19, 20) , TG.AC transgenic mice have normal skin (18, 21) . However, TG.AC mice differ from non-transgenic mice in that they develop skin tumors in response to wounding or following repeated treatments with tumor promoters such as TPA (18, 21) . Thus, the TG.AC mouse resembles a chemically initiated mouse.
Since many investigators have postulated that carcinogeninduced epidermal tumors arise from follicular stem cells (22) (23) (24) , we developed a K6/ODC transgenic mouse in which ODC overexpression is targeted to the outer root sheath cells of hair follicles with a keratin-6 promoter (25) . ODC has been shown to be strongly induced specifically in these perifollicular cells following multiple topical TPA treatments, which suggests that elevated levels of follicular ODC play an important role in tumor development (4). Here we describe the generation of double transgenic mice from a cross between K6/ODC transgenic and TG.AC v-Ha-ras transgenic mice. The TG.AC ras transgenic mouse was chosen since the precursors of squamous papillomas arise from focal hyperplasia of the upper epidermis of hair follicles in TPA-treated TG.AC transgenic mice (26) . Using the ODC/ras double transgenic model, we show that follicular expression of ODC co-operates with an activated Ha-ras gene to result in the rapid development of spontaneous malignant carcinomas in mice never treated with chemical carcinogens or tumor promoters.
Materials and methods

Animals
K6/ODC transgenic mice were generated as previously described (25) . Two K6/ODC lines from founder mice 39 and 55 (founder 39 having a higher ODC transgene copy number than 55) were maintained in the heterozygous state for the K6/ODC transgene while bred onto either a C57Bl/6J or DBA genetic background. K6/ODC transgenic mice were mated with either nontransgenic FVB/N mice (parental strain of TG.AC transgenic mice) or TG.AC mice homozygous for the v-Ha-ras transgene (obtained from Taconic Labs, Germantown, NY). Offspring heterozygous for both the TG.AC transgene and the K6/ODC transgene were identified by PCR genotyping. Mice were housed in shoebox cages in order to avoid wounding, and were observed twice a week for a maximum of 4 months for the appearance of skin tumors. In some cases, mice were administered DFMO in the drinking water at a concentration of 1% (w/v). Subsequent analyses of tissues from DFMOtreated mice have demonstrated that this dose of DFMO given orally, dramatically reduces the ODC activity and putrescine levels in skin within the first 2 days without any side-effects to the mouse. Since skin tumors develop in TG.AC mice following promotional stimuli such as wounding or TPA (18, 21) , some TG.AC mice were treated topically with TPA (5 ng in 200 µl acetone) twice a week for 3 weeks. TPA-induced tumors were removed for analyses 2-3 months after the last TPA treatment. For wounding or abrasion experiments, mice were first anesthetized with an i.p. injection of pentobarbital (69 µg/g body weight). For wounding, a 1.5 cm incision was made through the dorsal skin parallel to the midline and the edges of the wound approximated and closed with three clips. For abrasion, a 2 cm 2 area on the lower back was gently abraded with a felt-wheel on a motor tool leaving the abraded area shiny but bloodless (27) .
ODC and polyamines analyses
For analyses of tumor-free skin, the epidermis and dermis were separated by plunging excised skin into 55°C water for 20 s followed by scraping. To circumvent problems arising from tumor heterogeneity, tumors were frozen in liquid nitrogen, ground to a fine powder, and used for subsequent protein and polyamine analyses. For ODC enzyme activity and immunoblot analyses, the epidermal, dermal, and tumor tissues were homogenized in 25 mM TrisϪHCl, pH 7.5, 2.5 mM dithiothreitol, 0.1 mM EDTA, and protease inhibitors. Homogenates were assayed for ODC enzyme activity by quantifying the production of 14 CO 2 from L-[ 14 C]ornithine (New England Nuclear, Boston, MA) as previously described (3) . A portion of the epidermal, dermal, and tumor tissues were homogenized in 0.2 N perchloric acid for measurement of polyamine levels. Putrescine, spermidine, and spermine levels were determined by dansylation and separation on a reversed-phase C18 HPLC column.
Immunocytochemistry
Tissues were fixed in Fekete's solution (60% ethanol, 3.2% formaldehyde, and 0.75 M acetic acid) overnight and embedded in paraffin. Sections were processed for either hematoxylin and eosin (H&E) staining or immunocytochemistry using either rabbit ODC antiserum (a gift from Dr Oili Hietala, University of Oulu, Oulu, Finland) at a 1:500 dilution, rabbit keratin 6 antiserum (a gift from Dr Stuart Yuspa, NIH, Bethesda, MD) at a 1:2000 dilution, rat monoclonal 346-11A antibody to mouse β4 integrin (a gift from Dr Stephen Kennel, Oak Ridge National Laboratory, Oak Ridge, TN) at a 1:2000 dilution, or the monoclonal anti-proliferating-cell nuclear antigen Fig. 1 . ODC/ras double transgenic mice develop spontaneous skin tumors at an early, defined age. Heterozygous K6/ODC mice on a DBA/2J background were bred with homozygous TG.AC mice and observed for the appearance of spontaneous skin tumors. The percentage tumor incidence is the number of male and female mice with tumors at a given age/total number of ODC/ras double transgenic offspring. Table I . Incidence of spontaneous tumors in 10-week-old mice
a Heterozygous K6/ODC ϩ/-transgenic mice on either a DBA/2J or C57Bl/6J background were bred with TG.AC homozygous v-Ha-ras transgenic mice or the non-transgenic FVB/N parental strain. K6/ODC mice from two founder lines, 39 and 55, were used. b The K6/ODC -/-mice were the littermates of the K6/ODC ϩ/-mice. For each cross, the number of mice which developed tumors/number of offspring mice is given, with the incidence rate in parentheses.
(PCNA) antibody 19A2 (Coulter Immunology, Hialeah, FL). Slides were incubated with the appropriate biotinylated secondary antibody followed by an incubation with an avidin and biotinylated peroxidase complex (Vectastain Elite ABC kit; Vector Laboratory, Burlingame, CA) all at room temperature. Immunoreactive cells were localized by incubating the sections with a chromogen solution consisting of 1 mg/ml 3,3Ј-diaminobenzidine tetrahydrochloride (DAKO, Carpinteria, CA) and 0.02% H 2 O 2 , and then counterstained with hematoxylin, dehydrated, and mounted in Permount (Fisher Scientific, Pittsburgh, PA). Normal goat serum was used as the primary antibody to serve as negative controls.
In situ hybridization
Tumors were fixed in 4% paraformaldehyde, paraffin embedded, and sections processed for in situ hybridization as described previously (28) with a 35 S-labeled sense or antisense riboprobe to the SV40 polyadenylation/splice sequence of the v-Ha-ras transgene construct (18, 28) .
Results
Transgenic mice heterozygous for both the K6/ODC and the v-Ha-ras transgenes (ODC/ras) transgenic mice developed skin tumors at a very early age without prior treatment with a chemical carcinogen or tumor promoter (Table I) . Most tumors initially appeared within a very narrow window of 6-8 weeks of age ( Figure 1 ). The average tumor load was 12 tumors per mouse; however, there was wide variability ranging from 1 to 36 tumors per mouse. Control littermates heterozygous for only the v-Ha-ras transgene remained tumor-free when not treated with any tumor promoting agent (Table I) . Likewise non-initiated K6/ODC mice (on either a C57Bl or DBA genetic background) did not develop skin tumors even if promoted with TPA for several months. Interestingly, only 45% of the double transgenic mice that were progeny of K6/ODC transgenic mice on a C57Bl/6 background developed tumors, regardless of the K6/ODC founder line (39 or 55) used. A much higher percentage (76%) of the double transgenic offspring of K6/ODC mice on a DBA/2 background developed spontaneous tumors. These differences may be attributed to the welldocumented resistance of C57Bl/6 mice to the classical DMBA/ TPA tumor induction protocol (29) . All tumors were rapidly growing keratoacanthoma-like tumors that were typically cup-shaped having a central horny crater with cords of stratified squamous epithelium (30) . By 11 weeks of age, 62% of the tumor-bearing mice had developed large tumors that were Ͼ1 cm in diameter. Because of a large tumor burden, all mice were killed by 14 weeks of age. At 4-8 weeks from the first appearance of any tumors, more than half of the tumors had focal areas of conversion to a squamous cell carcinoma. In contrast, malignant skin tumors that developed in TPA-promoted TG.AC transgenic mice or DMBA-initiated/TPA-promoted carcinomas in non-transgenic mice require a longer period of development, often 8 months to a year (18, 29) . Whereas Ͼ50% of the spontaneous tumors in ODC/ras double transgenic mice converted to carcinomas within 8 weeks, no carcinomas were found in DMBA-initiated K6/ODC transgenic mice, even at 19 weeks following the appearance of the first tumor (15) . Thus, the ODC/ras spontaneous tumors grew faster, did not regress, and underwent malignant conversion much earlier than tumors that develop in TPA-treated TG.AC mice or in DMBA-initiated/TPA-promoted mice. Thus, elevated ODC/polyamine levels directed to hair follicles 'promote' skin tumor development in genetically 'initiated' transgenic mice possessing a mutated v-Ha-ras in the absence of any treatment with chemical carcinogens or tumor promoters.
Localization and levels of ODC, polyamines, and v-Ha-ras in tumors
A survey of tumors from the ODC/ras transgenic mice confirmed that these tumors had elevated levels of ODC enzyme activity that could be attributed to the expression of the fully active but truncated ODC protein product (11, 25) of the K6/ODC transgene (indicated by the lower arrow in Figure 2 ). As a result of the elevated ODC enzyme activity, putrescine levels were dramatically elevated in the spontaneous ODC/ras tumors compared with levels seen in non-tumorbearing, non-transgenic skin and even in the dermis of nontumor-bearing K6/ODC mice where the cells lining the dermal follicular cysts express high levels of ODC (25) . In contrast, TPA-induced tumors from the TG.AC transgenic mice lacking the K6/ODC transgene had a much lower ODC activity and putrescine content, a low level of immunodetectable endogenous ODC, and no truncated ODC protein. Spermidine levels were elevated in both ODC/ras tumors as well as ras tumors as compared with tumor-free skin, whereas spermine levels remained the same or decreased slightly in tumors. This suggests that putrescine and spermidine play an important role in the maintenance of skin tumors, both in the double transgenic mice as well as in the TPA-promoted TG.AC mice.
Immunohistochemistry revealed that elevated ODC expres-sion is localized to the suprabasal layers of ODC/ras tumors ( Figure 3A) . The co-localization of ODC expression in tumors with the suprabasal expression of keratin 6 ( Figure 3B ) suggests that the majority of ODC immunostained tumor cells expresses the K6/ODC transgene. Unlike normal epidermis, the suprabasal layers of these tumors exhibited many mitotic figures.
Immunohistochemical staining for proliferating-cell nuclear antigen (PCNA), an auxiliary protein of DNA polymerase, was used to detect proliferating cells (31) . Cellular proliferation was dramatically increased in cells of both the basal layer and the stratum spinosum of the ODC/ras tumors. Interestingly, PCNA-positive nuclei were also detected in cells lining the follicular cysts, and often the epidermal component of the tumors appeared to be continuous with these rapidly proliferating cells that line the follicular cysts found in K6/ODC transgenic mice ( Figure 3D ). Immunocytochemistry studies have shown that these epithelial cells lining the follicular cysts also possess high levels of ODC (25) . As observed in tumors from TPA-promoted TG.AC mice (28), the spontaneous tumors also expressed v-Ha-ras transgene mRNA ( Figure 3E and F).
Although the v-Ha-ras transgene mRNA was detected by in situ hybridization throughout all layers of the tumors, the strongest signal was in the basal epidermoid cells of the tumor ( Figure 3E ). Since these rapidly growing tumors underwent an early, high degree of conversion to malignant squamous cell carcinomas, we examined benign tumors for β4 integrin expression. Papillomas having high potential for conversion to malignancy have been reported to express the α6/β4 integrin complex suprabasally, whereas most low risk papillomas that eventually regress express the α6/β4 integrin on the basal surface of basal cells (32) . β4 integrin is expressed suprabasally in benign ODC/ras tumors ( Figure 3C ), which is not unexpected since none of the spontaneous ODC/ras tumors regressed and in fact many quickly underwent malignant conversion in Ͻ2 months. All of the spontaneous tumors in the double transgenic mice were keratoacanthomas, which, unlike in humans, do not tend to regress in mice (30) . We detected no suprabasal staining for β4 integrin in 4-week-old papillomas from TPA-treated TG.AC mice. However, at this early stage it is often difficult to predict whether a tumor will regress or will eventually progress to a carcinoma because most TPA-induced papillomas in TG.AC mice are of the low risk type with low conversion to squamous cell carcinomas (18) .
Tumor prevention and regression with DFMO
Administration of 1% DFMO in the drinking water from birth until 10 weeks of age prevented hair loss as well as tumor formation in ODC/ras mice. This dependency on ODC expression for the development of spontaneous tumors was further demonstrated when, at 10 weeks of age, these DFMO-treated mice were wounded in order to stimulate tumor formation. Since TG.AC mice develop tumors when promoted with a wounding stimulus (18), we made a 1.5 cm full skin incision in the dorsal skin followed by careful repair with wound clips. The wounding provided a non-chemical promotional stimulus in a defined area of the skin where tumor development could be more predictably observed. Five of the mice remained on DFMO drinking water, and the other five mice were taken off DFMO. Within 1-3 weeks all five mice on DFMO-free drinking water had developed tumors along the healed incision as well as some additional tumors away from the wound site. The number of tumors varied from three to 24 among these mice. 14) were also assayed for ODC activity. Whereas analyzed tumors in lanes 5-12 were from ODC/ras double transgenic mice that had never been treated with a chemical carcinogen or tumor promoter, the tumors analyzed in lanes 13 and 14 were from TG.AC homozygous mice that had been treated six times with TPA 2 months previously. Portions of the same tissues were processed for measurements of (b) putrescine, (c) spermidine, and (d) spermine. (e) Protein-equivalent amounts of epidermal, dermal, or tumor homogenates (same tissues as shown in lanes 1-14 in a-d) were analyzed for ODC protein by immunoblotting using a rabbit polyclonal-anti-ODC antibody. Note that the truncated ODC transgene product has a lower molecular weight compared with the wild-type ODC protein found in mouse kidney (K).
However, no tumors developed, including along the wound site, in the second group of five mice remaining on DFMO. At 4 weeks after wounding, DFMO was discontinued in this second group, and tumors developed along the wound site 5-6 weeks later. As a control group, TG.AC transgenic mice harboring a v-Ha-ras transgene, but no ODC transgene, were also wounded. In the absence of DFMO, tumors did not develop in these mice until 7-12 weeks after the wounding. However, the development of tumors was prevented in wounded TG.AC mice given DFMO in the drinking water. Thus, ODC inhibition not only prevented the formation of spontaneous tumors in ODC/ras mice but also prevented the formation of wound-induced tumors in genetically initiated mice carrying the v-Ha-ras transgene.
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At 4 weeks after wounding, DFMO administration was resumed in the first group of mice and their tumors completely regressed in Ͻ2 weeks. Interestingly, the tumors regressed in these DFMO-treated mice even though the v-Ha-ras transgene mRNA was still detected by RT-PCR in the wound area of these mice (data not shown). Tumor formation is therefore dependent upon ODC overexpression in this transgenic mouse model, and inhibition of ODC expression results in rapid regression of these tumors despite the expression of a mutated v-Ha-ras.
Discussion
Our data demonstrate that two genetic lesions, inappropriate ODC expression and a constitutively activated Ha-ras gene, (15), here we have focused on the synergy existing specifically between a mutated Ha-ras and ODC epidermal overexpression. It should be noted that carcinogens target many genes other than the endogenous Ha-ras gene, and these unidentified carcinogen-altered genes have been found to co-operate with the activated Ha-ras in DMBA/TPA-treated TG.AC mice to augment papilloma frequency, growth, and malignant conversion (33) . To our knowledge, this is the first report showing that ODC overexpression and an activated Ha-ras suffice to produce a high rate of malignant transformation in an animal model.
Genetic manipulation of transgenic and knockout animals provides a powerful method of studying synergistic interactions between genes. Co-operation experiments between various oncogenes such as v-Ha-ras, v-fos, and transforming growth factor (TGF)-α in the epidermis have demonstrated the necessity for multiple events in epithelial carcinogenesis (34) (35) (36) . When spontaneous papillomas developed at wound sites in transgenic mice with either v-Ha-ras or TGF-α overexpression in the epidermis, these tumors eventually regressed (19, (37) (38) (39) . However, both accelerated and enhanced papillomatogenesis occurred in double transgenic mice expressing either v-Ha-ras and v-fos (40), or TGF-α and v-fos (41) . Although these tumors were autonomous, with some growing to a massive size, none converted to carcinomas (40, 41) . In a similar fashion, TG.AC mice harboring a v-Ha-ras transgene only developed skin tumors if wounded or if promoted topically with TPA (18, 21) . However, a relatively high percentage of TPA-promoted tumors (30%) in TG.AG transgenic mice underwent malignant conversion within 1 year (18) . Genetic factors most likely play a role in the early malignant conversion of ODC/ras tumors, because FVB/N mice have been reported to have a high incidence of malignant carcinomas compared with other strains of mice (42, 43) . However, although the genetic background of ODC/ras double transgenic mice is 50% FVB/N, this probably was not the predominant factor in the early malignant conversion of their skin tumors, because none of the double transgenic mice expressing either v-Ha-ras and v-fos or TGF-α and v-fos (all of which are on a FVB/N genetic background) developed carcinomas (36, (39) (40) (41) .
Since previous studies using TPA-promoted TG.AC mice have reported that tumors appear to originate from cells around hair follicles (26) , expression of the v-Ha-ras transgene is most likely to occur in follicular cells. In contrast to other double transgenic models of epidermal neoplasia, the ODC/ras transgenic mouse has provided a means to direct ODC expression to these follicular cells that have been genetically initiated with a mutated ras gene. Abrasion experiments in ODC/ras double transgenic mice have shown that these mice develop spontaneous keratoacanthoma-like tumors in small patches of skin that were abraded when mice were 4 weeks old (data not shown). Abrasion removes only the epidermal layer of skin, and a new epidermal layer is regenerated from the follicular stem cells that remain in the lower part of the hair follicles residing in the dermal layer of the skin (27) . Thus, these spontaneous tumors must be of follicular origin rather than from interfollicular epidermal cells. This observation is consistent with our histological finding that the epithelial layers of ODC/ras tumors are often continuous with the epithelial cells lining the follicular cysts, which are characteristically found in K6/ODC transgenic skin. It is possible that the high conversion rate of TPA-induced tumors in TG.AC mice and of spontaneous ODC/ras tumors in the ODC/ras double transgenic mice may be because of their follicular origin. Thus, the cell population, which is targeted as well as the strong promotional influence of ODC expression, may play an important role in determining the neoplastic progression of epidermal tumors. Our study shows that the follicular expression of ODC in TG.AC mice promotes the expression of genes that are critical for the development of autonomous tumors that can undergo malignant conversion. However, the strong association of increased cellular proliferation with elevated ODC levels (as indicated by PCNA-stained nuclei in ODC/ras tumors) may not be the only mechanism by which ODC cooperates with a mutated ras to promote the growth and conversion of tumors to malignant carcinomas. Indeed, ODC overexpression in epidermal cells that have an activated Haras gene are more invasive in tracheal xenotransplants, and this is associated with elevated expression of stromelysin-1 and urokinase (14) .
Repeated treatments with the tumor promoter TPA are known to induce epidermal ODC, particularly in suprabasal perifollicular cells (4) . However, this TPA induction of ODC activity and putrescine is transient and quickly falls to low basal levels in contrast to the sustained high levels of ODC activity and putrescine in K6/ODC transgenic skin. Very little change in total intracellular levels of spermidine and spermine are found in either the non-tumor bearing skin or the spontaneous tumors of ODC/ras transgenic mice. Thus, our results suggest that the high sustained levels of ODC/putrescine in the spontaneous tumors of ODC/ras double transgenic mice are predominantly responsible for the more aggressive phenotype seen in these tumors compared with that seen in the TPAinduced tumors in TG.AC mice. Moreover, DFMO, which specifically inhibits ODC, not only dramatically reduces both ODC activity and putrescine levels, but also causes a rapid regression of tumors.
The ODC/ras double transgenic mouse provides a simple in vivo model in which to test downstream effectors that play a key role in mediating the development of tumors that result from the synergistic co-operation between ODC and Ha-ras activation and that play a key role in the development of tumors. The total dependency of these tumors on ODC expression, their regression with the ODC inhibitor, DFMO, and the rapid conversion to carcinomas underscores the important role that follicular ODC expression plays in the initial development and maintenance of skin tumors as well as in malignant conversion.
